Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

NCT01740531 is registered in ClinicalTrials.gov with Cerus Corporation as lead sponsor.

NCT NCT01740531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01740531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion
Lead sponsor
Cerus Corporation
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2012
Completion date
December 31, 2017
Enrollment
86 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

thalassemia major